Skip to main content
Clinical Trials/CTRI/2019/07/019999
CTRI/2019/07/019999
Completed
未知

Safety in use study to assess the cutaneous tolerance of mentholated topical ointment in healthy children and adult human subjects under normal conditions of use.

The Procter Gamble Company0 sites120 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
The Procter Gamble Company
Enrollment
120
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
August 20, 2019
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Age: For adult 18 to 65 years (both inclusive) and for children 6 to 12 years (both inclusive) old at the time of consent.
  • 2\. Sex: For adult, Healthy male and Non\-pregnant/non\-lactating females, For Children, Healthy Male and femaleâ??s child.
  • 3\. Females of childbearing potential and menarche children both must have a negative urine pregnancy test performed on screening visit.
  • 4\. Subjects are in good general health as determined by the Investigator on the basis of medical history reported by subjects and subjectâ??s Parent/legal guardian/caregiver.
  • 5\. Adult subjects must be able to understand and provide written informed consent to participate in the study.
  • 6\. Written informed consent from the Parent/legal guardian/caregiver and verbal/oral assent from children between 6 to 12 years of age in the presence of their parent/legal guardian/caregiver.
  • 7\. No moisturizers, oil, cream, any other ointment or perfume can be used in the chest, neck or back area for the duration of the study; however, subjects may use their normal product(s) for washing their hair, hands and face.
  • 8\. Should be current users of skin ointment/skin balm, e.g. Vicks VapoRub, Zandu Balm, and Tiger Balm, Amrutanjan or similar product.
  • 9\. Subjectâ??s participating parent/legal guardian/caregiver must be able to provide government authorized legal proof of childâ??s to participate in the study.
  • 10\. Subjects and subjectâ??s participating parent/ legal guardian/caregiver should be willing and able to follow the study directions to participate in the study.

Exclusion Criteria

  • 1\. Pregnant or lactating female subjects should be excluded as these conditions impact the condition of the skin.
  • 2\. Subjects who have a clinically significant active dermatitis or skin disease anywhere on the body (excluding facial acne).
  • 3\. Subjects who have a history of psoriasis, eczema or skin cancer.
  • 4\. Subjects who have a condition or are taking medication(s) which, in the judgment of the Investigator or Designate, makes the subject ineligible or places the subject at undue risk.
  • 5\. Subjects who have received treatment (chemotherapy, radiation, immune suppressant medications) for any type of cancer within the last 6 months.
  • 6\. Subjects who have history of a mastectomy or axillary lymph nodes removed.
  • 7\. Subjects who have history of an autoimmune or immune deficiency disease (e.g. lupus, myositis, Crohns disease, autoimmune thyroid diseases, autoimmune hepatitis, etc.).
  • 8\.Subjects who are currently taking any immunosuppressant medication.
  • 9\. Subjects who have history of insulin\-dependent diabetes.
  • 10\. Subjects who have history of asthma or any other chronic respiratory condition requiring daily therapy.

Outcomes

Primary Outcomes

Not specified

Similar Trials